NFL Rookie Quessenberry Diagnosed with Lymphoma

Professional football player David Quessenberry, a tackle for the Houston Texans, has been diagnosed with lymphoma. The diagnosis comes after a brief period during which Quessenberry had a chronic chest cold and experienced shortness of breath during practice.

"The goal of David's treatment is to cure the disease," said his agents at Rep 1 Sports in a statement issued on Twitter. "So he can return to the life that he has worked so hard to earn. David is extremely positive and determined to win this fight against cancer. Our love for David is strong and we are praying for him and his family during this difficult time. All your positive thoughts and prayers for David are encouraged and appreciated."

Quessenberry was drafted by the Houston Texans in the sixth round of the 2013 NFL draft out of San Jose State University. He plays offensive tackle, and although he didn't get into any games last season, and following his diagnosis he will be put temporarily on the practice squad.

No word on what subtype of lymphoma he has been diagnosed with, or what kind of treatments he may be starting soon.

Fortunately for Quessenberry, he is from Houston, where the MC Anderson Cancer Center is located, widely regarded as one of the very best cancer centers in the world.

Source: Various outlets

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap